<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3357">
  <stage>Registered</stage>
  <submitdate>14/11/2011</submitdate>
  <approvaldate>14/11/2011</approvaldate>
  <nctid>NCT01473043</nctid>
  <trial_identification>
    <studytitle>Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment</studytitle>
    <scientifictitle>Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A4061061</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Axitinib

Treatment: drugs: Axitinib
5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Metastatic renal cell carcinoma with a component of clear cell subtype.

          -  Prior first line systemic therapy

          -  At least 1 measurable lesion as per Response Evaluation Criterion in Solid Tumors
             [RECIST 1.1].

          -  Adequate hematology, liver and kidney functions

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1.

          -  Life expectancy of =12 weeks.

          -  Normotensive or well controlled hypertension (less than/equal to 140/90 mm Hg.)

          -  Negative pregnancy test

          -  Adequate recovery time from prior systemic therapy, surgery or radiation

          -  Willing and able subjects who have signed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  More than one prior systemic therapy regimen

          -  Major bowel-penetrating surgery &lt;4 weeks

          -  Active gastro intestinal bleed in past 3 months

          -  Active peptic ulcer disease in the past 6 months

          -  Current or anticipated use of potent CYP3A4/5 inhibitors

          -  Current or anticipated use of known CYP3A4/5 or CYP1A2 inducers

          -  Requirement for therapeutic warfarin or high dose steroids

          -  Symptomatic or untreated brain metastases

          -  A serious uncontrolled medical disorder or active infection

          -  Pregnant or breastfeeding females

          -  History of another active malignancy

          -  Dementia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Expanded Access</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>No longer available</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,TAS,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Douglas</hospital>
    <hospital>Pfizer Investigational Site - Hobart</hospital>
    <hospital>Pfizer Investigational Site - Wendouree</hospital>
    <postcode>4814 - Douglas</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3355 - Wendouree</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell
      variant), who have failed first line therapy. The study will recruit a maximum of 30 patients
      from 2 countries including Australia and Canada. Patients will be followed up for efficacy,
      safety and health related outcomes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01473043</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>